Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy
Cesta CE, Rotem R, Bateman BT, et al.
JAMA Intern Med. 2023:e236663.
Leggi
Breaking news
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial
Aronne LJ, Sattar N, Horn DB, et al.
JAMA. 2023:e2324945.
Leggi
Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
Igweokpala S, Sule NO, Douros A, et al.
Diabetes Obes Metab. Pub. online 29 Nov 2023.
Leggi
Child-to-adult body size change and risk of type 2 diabetes and cardiovascular disease
Carrasquilla GD, Ängquist L, Sørensen TIA, et al.
Diabetologia. Pub. online 12 Dec 2023.
Leggi
Continuous glucose monitoring systems in non-insulin-treated people with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Oliva Morgado Ferreira R, Trevisan T, Pasqualotto E, et al.
Diabetes Technology & Therapeutics. Pub. online 13 Dec 2023.
Leggi
Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes
Liu Z, Peng Y, Li S, et al.
BMC Endocr Disord. 2023;23(1):272.
Leggi
Occurrence of gastrointestinal adverse events upon glp-1 receptor agonist initiation with concomitant metformin use: a post hoc analysis of LEADER, STEP 2, SUSTAIN 6, and PIONEER 6
Klein KR, Clemmensen KKB, Fong E, et al.
Diabetes Care. 2023:dc231791.
Leggi
Effect of the dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Bantounou MA, Sardellis P, Thuemmler R, et al.
Diabetes Obes Metab. Pub. online 29 Nov 2023.
Leggi
Patterns of telemedicine use and glycemic outcomes of endocrinology care for patients with type 2 diabetes
Zupa MF, Vimalananda VG, Rothenberger SD, et al.
JAMA Netw Open. 2023;6(12):e2346305.
Leggi
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
The EMPA-KIDNEY Collaborative Group
The Lancet Diabetes & Endocrinology. Pub. online 4 Dec 2023.
Leggi